CHICAGO, Aug 7 (Reuters) – Five major U.S. health systems said they would offer Eisai and Biogen’s promising new Alzheimer’s drug Leqembi after working out payment and administrative policies, and how to assess and monitor patients, most likely in the next month or two.Leqembi, which won full U.S. regulatory approval last month, is the first […]
